Progressive fibrotic lung disease is one of the possible consequences of COVID-19
pulmonary pneumonia, and it is one of the most worrying long-term complications.
Pulmonary fibrosis is associated with non-reversible lung dysfunction which leads to
decreased blood oxygen saturation at room air and dyspnea; eventually leaving the
patient with oxygen dependency
Signs and symptoms of pulmonary fibrosis may include:
● Shortness of breath (dyspnea)
● Dry cough
● Unexplained weight loss
● Aching muscles and joints
How pulmonary fibrosis is managed traditionally
Currently, no fully proven options are available for the treatment of post inflammatory
COVID-19 pulmonary fibrosis. Various treatment strategies are under evaluation. It has
been proposed that prolonged use of antiviral, anti-inflammatory and anti-fibrotic drugs
diminish the probability of development of lung fibrosis. However, it is yet to be
ascertained whether early and prolonged use of antiviral agents may prevent remodeling
of lungs or which of the available antivirals is more effective.
How Post Covid fibrosis can be treated with stem cells?
Our bodies are made up of different types of cells, like brain cells, blood cells, heart cells,
skin cells and stem cells. Stem cells can turn into many other types of cells and secrete
many growth factors.
The Growth Factors secreted by Mesenchymal Stem Cell (MSC) therapy works on selective stoppage of the signalling pathway by causing immunomodulatory effects that ameliorate the pulmonary fibrosis through paracrine signaling. This leads to betterment of symptoms of fibrosis.